Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00760019 · ClinicalTrials.gov registry record · Phase 2

Inflammation and Vascular Function in Atherosclerosis

A Phase 2 study of Atherosclerosis, sponsored by Brigham and Women's Hospital.

Completed
Registry status
Phase 2
Development phase
58
Enrollment target
1
Study location

NCT00760019 is a Phase 2 study of Atherosclerosis that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 58 participants, below the 1,065-participant average among 69 other Atherosclerosis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00760019, a Phase 2 study of Atherosclerosis, has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
Phase 2
Development phase
58 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether reducing inflammation in blood vessels with an aspirin-like drug called salsalate will improve blood vessel function.

Conditions Studied

Interventions

  • DRUG placebo
  • DRUG salsalate

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2005-08
Est. Completion 2011-02
Phase Phase 2

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT00760019

The ClinicalTrials.gov registry entry for NCT00760019 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,065-participant average among 69 other Atherosclerosis trials with a reported enrollment target (95% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atherosclerosis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00760019 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00760019 about?

NCT00760019 is a clinical study titled "Inflammation and Vascular Function in Atherosclerosis". The purpose of this study is to determine whether reducing inflammation in blood vessels with an aspirin-like drug called salsalate will improve blood vessel function.

What is the current status of trial NCT00760019?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2005-08. Estimated completion is 2011-02.

What conditions does trial NCT00760019 study?

This clinical trial studies the following conditions: Atherosclerosis.

What interventions are being tested in trial NCT00760019?

The interventions under investigation include: placebo (DRUG), salsalate (DRUG).

Who is sponsoring clinical trial NCT00760019?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00760019 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Atherosclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.